Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A, Lonardi S, Rosati G, Di Bartolomeo M, Ronzoni M, Pella N, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Barni S, Rulli E, Labianca R; TOSCA Investigators. Sobrero A, et al. Among authors: pella n. J Clin Oncol. 2018 May 20;36(15):1478-1485. doi: 10.1200/JCO.2017.76.2187. Epub 2018 Apr 5. J Clin Oncol. 2018. PMID: 29620994 Clinical Trial.
Cisplatin and gemcitabine in non-small-cell lung cancer.
Cartei G, Sacco C, Sibau A, Pella N, Iop A, Tabaro G. Cartei G, et al. Among authors: pella n. Ann Oncol. 1999;10 Suppl 5:S57-62. doi: 10.1093/annonc/10.suppl_5.s57. Ann Oncol. 1999. PMID: 10582141 Free article. Review.
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Guglielmi A, Barni S, Zaniboni A, Pella N, Belvedere O, Beretta GD, Grossi F, Frontini L, Puglisi F, Labianca R, Sobrero A; Gruppo Italiano Studio Carcinomi Apparato Digerente. Guglielmi A, et al. Among authors: pella n. Br J Cancer. 2004 Oct 18;91(8):1428-33. doi: 10.1038/sj.bjc.6602176. Br J Cancer. 2004. PMID: 15381935 Free PMC article. Clinical Trial.
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G. Cecchin E, et al. Among authors: pella n. Pharmacogenomics J. 2013 Oct;13(5):403-9. doi: 10.1038/tpj.2012.31. Epub 2012 Aug 7. Pharmacogenomics J. 2013. PMID: 22868256 Free PMC article.
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G. Cecchin E, et al. Among authors: pella n. Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21. Pharmacogenomics J. 2015. PMID: 25331073
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: pella n. Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828. Sci Rep. 2014. PMID: 25370899 Free PMC article. Clinical Trial.
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
Garziera M, Bidoli E, Cecchin E, Mini E, Nobili S, Lonardi S, Buonadonna A, Errante D, Pella N, D'Andrea M, De Marchi F, De Paoli A, Zanusso C, De Mattia E, Tassi R, Toffoli G. Garziera M, et al. Among authors: pella n. PLoS One. 2015 Dec 3;10(12):e0144000. doi: 10.1371/journal.pone.0144000. eCollection 2015. PLoS One. 2015. PMID: 26633805 Free PMC article.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators. Lonardi S, et al. Ann Oncol. 2016 Nov;27(11):2074-2081. doi: 10.1093/annonc/mdw404. Epub 2016 Aug 29. Ann Oncol. 2016. PMID: 27573560 Free article. Clinical Trial.
Immunotherapy for colorectal cancer: where are we heading?
Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G. Basile D, et al. Among authors: pella n. Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Expert Opin Biol Ther. 2017. PMID: 28375039 Free article. Review.
70 results